Suzanne E. Wardell - Concepedia

Author

Suzanne E. Wardell

Also Known As

Anders Bergh, Liu, Siyao, S E Wardell, S Wardell, S. Wardell, Stephan Wardell, Suzanne E Wardell, Suzanne E. Wardell, Suzanne Wardell, Wardell, Suzanne E.

155

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

Duke University University of Illinois Urbana-Champaign University of Colorado Health University of Illinois Chicago University of North Carolina at Chapel Hill

About

Suzanne E. Wardell is an author at Duke University specializing in medicine, pharmacology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	22	2.5K
2	Natural Sciences	4	4	403
3	Engineering	1	1	17
4	Health Sciences	1	1	197
5	Allergy	1	1	20

Suzanne E. Wardell

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology Erik R. Nelson, Suzanne E. Wardell, Jeff S. Jasper, Science Tumor BiologyBreast OncologyOncology27-Hydroxycholesterol Links HypercholesterolemiaMedicine	2013	819
The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells Amy E. Baek, Yen-Rei A. Yu, Sisi He, Nature Communications	2017	409
Systematic identification of signaling pathways with potential to confer anticancer drug resistance Colin A. Martz, Kathleen Ottina, Katherine R. Singleton, Science Signaling Drug TargetBreast OncologyCancer BiologyTamoxifen SensitivityTumor Biology	2014	197
A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product Maria V. Liberti, Ziwei Dai, Suzanne E. Wardell, Cell Metabolism Medicinal ChemistryDrug TargetDrug TargetingBiochemistryNatural Sciences	2017	196
Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer Donald P. McDonnell, Suzanne E. Wardell, John D. Norris Journal of Medicinal Chemistry Breast OncologyGynecologyPharmacotherapyMammary Gland DevelopmentEndocrine Oncology	2015	170
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Suzanne E. Wardell, Matthew J. Ellis, Holly M. Alley, Clinical Cancer Research	2015	153
The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy Suzanne E. Wardell, Jeffrey R. Marks, Donald P. McDonnell Biochemical Pharmacology Endocrine MechanismMedicineHormonal ReceptorPhysiologySaturable Process	2011	136
Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease Suzanne E. Wardell, Erik R. Nelson, Christina Chao, Clinical Cancer Research	2013	136
Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors Grace R. Anderson, Suzanne E. Wardell, Catherine Yip, Nature Communications	2018	135
Obesity, Cholesterol Metabolism, and Breast Cancer Pathogenesis Donald P. McDonnell, Sung Hee Park, Matthew T. Goulet, Cancer Research Breast OncologyPathologyTumor BiologyObesityMetabolic Syndrome	2014	111

Page 1